The Globe and Mail reports in its Thursday, March 13, edition that Raymond James analyst Michael Freeman has commenced coverage on Healwell AI with an "outperform" recommendation and a $3 share target. The Globe's David Leeder writes in the Eye On Equities column that analysts on average target the shares at $4.14. Mr. Freeman says in a note: "Healwell AI is a multi-modal health-care company that provides end-to-end health-care data solutions for enterprise and public sector customers, health care AI solutions for physicians and health systems to support preventative patient care, and clinical development solutions for large life science and pharma partners. Healwell AI's growing basket of services, which includes globally -- and nationally (Canada) -- relevant digital front door and digital care record platforms, AI-first disease detection technologies, clinical data insight generation capabilities, a full-service clinical research organization, and a deep strategic partnership with WELL Health -- Canada's largest pool of clinics -- are driving the company's emergence as a global health-care data powerhouse and a go-to partner to large life science companies for accelerating clinical development."